Select Your Region

We noticed you visit this page from United States. Please select your preferred region to continue.

skip to content

Country Selector

Based on your location

Europe

North America

Latin America

Asia-Pacific

Healthcare Sector Verification

This section contains information intended for healthcare professionals.

Please confirm that you are affiliated with a healthcare organization.

Anti-MCV in RA-ILD: New Insights into Diagnosis and Clinical Relevance

Insights into anti-MCV as a potential marker of pulmonary involvement in RA.

Published: 16/11/2026 | Modified: 16/11/2026
  • RA-ILD is a serious complication of rheumatoid arthritis, with early identification of pulmonary involvement remaining an important clinical challenge.
  • Anti-MCV antibodies may provide valuable insights into RA-associated lung disease, potentially complementing established serological and clinical markers.
  • This scoping review examines the current evidence on the diagnostic and clinical significance of anti-MCV antibodies in patients with RA-ILD and highlights the need for prospective validation.

Test associated with this resource

Related instrument

Discover more resources on Rheumatoid Arthritis

This section contains information intended for wide distribution and may therefore contain product details or information that is not available or valid in your country. Please contact your local Sebia representative. Information intended for healthcare professionals. Carefully read the instructions in the reagent package inserts and instrument manuals.